Covalent eIF4E Inhibitors for Selective Translation Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a significant need for compounds that specifically inhibit eukaryotic initiation factor 4E (eIF4E) activity, particularly in the regulation of cancer pathways, as elevated levels of eIF4E are associated with various tumors and cancer cell lines, and current treatments are inadequate.
Innovation Solution
Development of covalent inhibitors that bind specifically to eIF4E, disrupting its function and reducing the translation of malignancy-associated mRNAs, thereby inhibiting cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If covalent inhibitors are developed to bind specifically to eIF4E, then the specificity and potency of eIF4E inhibition is improved, but the complexity of compound design and synthesis increases
Solution Approach 1:
The covalent inhibitor is divided into two functional segments: a warhead containing the electrophilic moiety (R group) that covalently modifies eIF4E, and a linker (X group) that connects to the core structure. This segmentation allows independent optimization of each component - the electrophilic moiety provides specificity through covalent binding while the linker provides structural flexibility and pharmacokinetic properties.
Solution Approach 2:
The patent systematically varies chemical parameters including the type of electrophilic moiety (R group), the linker structure (X group), and the core scaffold to optimize both specificity and potency. By changing these chemical parameters, the invention achieves reliable eIF4E inhibition while managing design complexity through structured molecular optimization.
2Duration of action of moving object
If covalent binding is used to inhibit eIF4E activity, then the duration of inhibition is improved, but the risk of off-target effects and toxicity increases
Solution Approach 1:
The electrophilic moiety (R group) is positioned at a specific location in the molecule to react with a particular amino acid residue in the eIF4E binding pocket. This localized reactivity ensures that covalent modification occurs only at the intended target site within eIF4E, providing prolonged inhibition while minimizing off-target effects through spatially restricted chemical reactivity.
Solution Approach 2:
The linker (X group) acts as an intermediary between the core structure and the electrophilic moiety, providing spatial separation and directional control. This intermediary structure helps position the electrophilic group precisely at the eIF4E binding interface, ensuring that covalent binding occurs only at the intended location and reducing the risk of non-specific reactions with other cellular proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The covalent inhibitors effectively attenuate eIF4E activity, potentially leading to reduced cancer cell proliferation and providing a targeted therapeutic approach for eIF4E-dependent diseases.
Implementation Method 1
translational inhibitors that bind covalently with eukaryotic initiation factor 4E (eIF4E)
Data Source
AI summary
The present invention is directed to novel translational inhibitors that bind covalently with eukaryotic initiation factor 4E (eIF4E) and inhibit or modulate the activity of eIF4E, as well as stereoisomers, tautomers and pharmaceutically acceptable salts of such compounds. The present invention also is directed to pharmaceutically acceptable compositions containing such translational inhibitors and associated methods for treating conditions that would benefit from eIF4E inhibition including, but not limited to, treatment of inflammation and various cancers.